The IPO is entirely a fresh issue of 1 crore shares of ₹126 crore.
Amanta Healthcare plans to use ₹70 crore of the proceeds for expansion of its SteriPort manufacturing line, ₹30.1 crore for setting up a new line for SVPs, and the balance for general corporate purposes.Company overviewIncorporated in December 1994, Amanta Healthcare is a pharmaceutical company that specialises in the development, manufacturing, and marketing of a diverse array of sterile liquid products, specifically parenteral products, which are packaged in plastic containers utilizing Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. The company is also a manufacturer of medical devices.
The company has a strong domestic presence, with over 320 distributors and stockists, and also exports to Africa, Latin America, the UK, and other emerging markets. As of FY25, 55% of its revenue came from domestic branded generics, 33% from international sales, and 10% from product partnering and contract manufacturing.
Amanta Healthcare’s consolidated revenue stood at ₹274.7 crore in FY25, down slightly from ₹280.3 crore in FY24. Profit after tax, however, improved sharply to ₹10.5 crore in FY25 as against ₹3.6 crore in FY24.
Beeline Capital Advisors is the sole book running lead manager and MUFG Intime India is the registrar to the issue.
The allotment for the Amanta Healthcare IPO is expected to be finalised on September 4, while the company’s shares will be listed on BSE and NSE with a tentative listing date fixed as September 9.
